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Case reports of severe IPH requiring liver transplantation are very rare. We report the 
case of a 65-year-old woman who was diagnosed as having idiopathic portal 
hypertension (IPH). At the age of 60 years, her initial symptom was hematemesis due to 
ruptured esophageal varices. Computed tomography of the abdomen showed 
splenomegaly and a small amount of ascites without liver cirrhosis. She was diagnosed 
as having IPH and followed-up as an outpatient. Five years later, she developed 
symptoms of a common cold and rapidly progressive abdominal distension. She was 
found to have severe liver atrophy, liver dysfunction and massive ascites. Living donor 
liver transplantation was then performed and her postoperative course was uneventful. 
Histopathological findings of the explanted liver showed collapse and stenosis of the 
peripheral portal vein. The areas of liver parenchyma were narrow while the portal 
tracts and central veins were approximate one another, leading to a diagnosis of IPH. 
There was no liver cirrhosis. The natural history of refractory IPH could be observed in 




 Idiopathic portal hypertension (IPH) is a relatively rare disease, and it has been 
reported mostly in patients from Japan 1). Most IPH patients have a good prognosis with 
treatment for their esophagogastric varices, but some IPH cases develop end-stage liver 
failure despite various medical treatments2-11). Such end-stage liver failure is an 
indication for liver transplantation, but details of such cases have not been fully reported 
in the literature. We treated a patient with severe IPH who required living donor liver 




A 65-year-old woman who had been followed-up for IPH at our hospital developed 
abdominal distension. At the age of 60 years, the patient presented with sudden 
hematemesis and was taken to a nearby hospital. On emergent upper gastrointestinal 
endoscopy, the ruptured esophageal varices were successfully ligated. Subsequently, the 
patient was transferred to our hospital. 
 On admission, her vital signs (heart rate, blood pressure, respiratory rate, and body 
temperature) were stable. On physical examination, her abdomen was soft, flat, and 
non-tender. Her spleen was palpable, but her liver was not palpable. She did not have 
encephalopathy. The patient denied any history of blood transplantation, alcohol abuse, 
or medications. Laboratory data showed pancytopenia (hemoglobin, 9.4g/dL; platelet 
count, 4.5 x 104/μL; and white blood cell count, 1,300 /μL). Liver and renal function 
tests and electrolytes were normal. Her prothrombin time was slightly prolonged (73%). 
Hepatitis B surface antigen, hepatitis C virus antibody, and anti-mitochondoria antibody 
were all negative. 
 Computed tomography of the abdomen showed splenomegaly, incomplete extrahepatic 
portal vein thrombus, and a slight volume of free peritoneal fluid, but no hepatomegaly, 
liver cirrhosis, or liver tumors (Fig. 1A). The gastrointestinal tract, gallbladder, pancreas, 
kidneys, and genital organs were unremarkable. There was no obstruction of the 
extrahepatic portal vein or the inferior vena cava. Upper gastrointestinal endoscopy 
showed persistent esophageal varices.  
 The patient had portal hypertension that consisted of esophageal varices, splenomegaly, 
and pancytopenia. Liver function was completely normal at laboratory data, and liver 
cirrhosis was not found on imaging diagnosis, though liver biopsy was not performed. 
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Obstruction of the extrahepatic portal vein and the inferior vena cava, hematological 
malignancies, or other known diseases was ruled out. IPH was diagnosed, and she was 
followed routinely at our hospital as an outpatient during which she was prescribed 
propranolol and warfarin. Her condition remained quite stable and uneventful for five 
years. 
 At the age of 65 years, she developed symptoms of the common cold and rapidly 
progressive abdominal distension. At that time, laboratory data showed anemia 
(hemoglobin, 7.5 g/dL), but normal platelet and white cell counts. Serum aspartate 
aminotransferase, alanine aminotransferase, and total bilirubin levels were normal. Her 
serum albumin level was decreased to 2.6 g/dL. Her prothrombin time was 44%, which 
was drastically prolonged, despite vitamin K administration. She also had acute renal 
failure (blood urea nitrogen, 61 mg/dL; and serum creatinine, 3.8 mg/dL). Computed 
tomography showed massive ascites, and volumetry showed that her liver was atrophic, 
with only 44% of the volume of that 5 years earlier (Fig. 1B). Extrahepatic portal vein 
thrombus which was found 5 years earlier was disappeared. The Child-Pugh score was 
11 points, and the model of end-stage liver disease (MELD) score was 23 points. She 
was diagnosed as having non-reversible, end-stage liver failure, and she underwent liver 
transplantation. 
 At laparotomy, she had 15 L of free intraperitoneal fluid. The liver was extremely 
atrophic; the resected whole liver weight was only 620g. An extended left lobe liver 
graft, weighting 400 g, was transplanted from her husband. The graft weight standard 
liver volume rate was 36.8%. A total splenectomy was also performed. The patient’s 
postoperative course was uneventful, and she was discharged at 50 days after surgery. 
Five months after transplantation, the patient developed enterocolitis caused by 
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cytomegalovirus infection; she died from peritonitis following perforation of the small 
intestine. 
 The explanted liver at the time of the LDLT was atrophic with a wavy surface. On 
histopathology, there was collapse and stenosis of the peripheral portal vein (Fig. 1C). 
The areas of liver parenchyma had become narrow so that the portal tracts and central 
veins were approximate one another. The entire specimen showed narrowing of the liver 
parenchyma, which was especially severe near the capsule. Inflammatory cells 
collection and dilated abnormal vessels were seen around the portal tracts. There were 
no pseudolobules or bridging folds. The histopathological findings were compatible 
with IPH. There was no liver cirrhosis or evidence of malignancy.
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Discussion 
Portal hypertension is usually caused by liver cirrhosis, but some cases of portal 
hypertension occur without cirrhosis. Sinusoidal portal hypertension of unknown 
etiology is regarded as IPH clinically. When diagnosing IPH, one must rule out liver 
cirrhosis, obstruction of the extrahepatic portal vein and the inferior vena cava, blood 
diseases, parasitic diseases, granulomatous hepatic disease, congenital liver fibrosis, 
chronic viral hepatitis, primary biliary cirrhosis, and other known diseases.12) IPH has 
been found in 2.1% to 2.6% of livers at autopsy.13, 14) IPH is associated with a spectrum 
of histological lesions, including incomplete septal cirrhosis, nodular regenerative 
hyperplasia, and partial nodular transformation.14-16) The lesions show some degree of 
uneven fibrosis but may coexist in the same liver. In our case, typical findings of 
incomplete septal cirrhosis, nodular regenerative hyperplasia, or partial nodular 
transformation were not seen. The pathogenesis of IPH is unclear, but it can occur in 
association with a variety of developmental, vascular, collagen vascular, or biliary tract 
diseases.6, 8, 11) Renal failure with or without transplantation and the toxic effects of 
some drugs may be related to IPH.5, 8, 10, 11) Common symptoms of IPH include 
splenomegaly, pancytopenia, gastrointestinal bleeding, ascites, and encephalopathy.  
IPH patients can be treated by the usual approaches: a) chronic medical therapy, along 
with balloon tamponade and vasoactive drugs for bleeding esophageal varices; b) 
endoscopic variceal ligation and sclerotherapy for both chronic and acute treatment; and 
c) portosystemic shunt procedures (portocaval, mesocaval, or radiological) or 
devescularization surgery.8) In general, IPH dose not progress to liver cirrhosis or 
hepatocellular carcinoma. The prognosis for IPH patients is mostly good, if the 
gastrointestinal bleeding can be controlled. However, some IPH cases progress to 
 9
end-stage liver failure.  
In our case, the patient developed symptoms of the common cold and rapidly 
progressive abdominal distension. Collagen diseases and autoimmune disorders are 
known as associated with IPH.10, 11) Immune system plays a role in IPH, so infection 
may be one of progressive factors for IPH. Though decrease of hepatic blood flow is 
considered to relate to IPH progression, it is unclear whether decrease of hepatic blood 
flow affected acute deterioration in this case.11)  Portal vein thrombus is one of causes 
for decrease of hepatic blood flow, but it was not found in operation and explanted liver 
specimen.     
 Some IPH patients who are resistant to all other therapies may be successfully treated 
with orthotopic liver transplantation (OLT). Several case reports dealing with OLT for 
severe IPH are summarized in Table 1 2-11). Taking into account these previous reports 
and the present, there were 40 patients (30 men, 10 women) with a mean age at 
transplantation of 45.5 years (range: 20-65 years). Gastrointestinal varices, 
splenomegaly, and ascites were commonly seen in severe IPH patients who required 
OLT, but these symptoms are common in IPH (Table 2). No specific symptoms 
characterize severe IPH. Eleven patients were treated for varices, seven with 
sclerotherapy and four with endoscopic variceal ligation, and 9 patients underwent 
pretransplantation porto-systemic shunting procedures (6 transjugular intrahepatic 
porto-systemic shunts and 3 mesocaval shunts) (Table 3). The time between the clinical 
manifestations of portal hypertension and liver transplantation ranged from 2 months to 
14 years, with a mean of 4.6 years. Patients underwent OLT because of rapidly 
progressive, life-threatening complications of portal hypertension and liver disease and 
the inefficacy of surgical or radiological porto-systemic shunting. Combined liver and 
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renal transplantation is performed in patients with associated severe renal failure.5, 8, 10) 
Most patients with severe IPH in the literature were well following OLT. Four patients 
died in the early posttransplantation period, due to herpes zoster encephalitis, suicide, 
sudden rupture of an unsuspected splenic aneurysm, and pneumonia.2, 8, 11) Three 
patients showed evidence suggestive of recurrent with IPH in the graft liver. One patient 
developed symptoms one year after OLT;11) 2 patients were asymptomatic, though their 
liver biopsy findings after OLT suggested recurrence.8, 11)  
 Making a pretransplantation diagnosis of IPH is difficult; 23 of the 40 patients with 
IPH were clinically believed to have cirrhosis, based on the clinical presentation, the 
pretransplantation biopsy findings, or the radiological images. The diagnosis was made 
only after post-transplant examination of the explanted liver. In cases who died from 
what appeared to be liver cirrhosis clinically, some had hidden IPH. In cases with 
symptoms of severe portal hypertension without liver dysfunction, IPH should be 
considered. 
 In conclusion, appropriate treatment can provide IPH patients with a good prognosis, 
but some patients with IPH develop end-stage liver failure. Some patients who are 
clinically diagnosed as having cryptogenic cirrhosis may have IPH. Patients with severe 
IPH who are resistant to other therapies may be good candidates for OLT, after which a 
favorable outcome can be expected.   
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Figure Legends 
Fig. 1: A. Computed tomography at the time of the first admission shows splenomegaly 
and incomplete extrahepatic portal vein thrombus (arrow). No liver cirrhosis or liver 
tumor is seen. B. Computed tomography 5 years after the first admission shows massive 
ascites and a very atrophic liver. C. Histopathological findings show collapse of the 
peripheral portal vein. Inflammatory cells and dilated abnormal vessels are seen near the 
portal tract (Hematoxylin and eosin stain). 
Table 1  summary of case reports with severe IPH required liver transplantation
span between explanted
author year cases gender age at LT diagnosis before LT manifestation and LT liver weight pathological diagnosis prognosis
McDonald2) 1990 1 male 47 cirrhosis 10 years 973g NRH died (4 months)
Le Bail3) 1990 1 male 48 recurrent HCC N / A N / A HCC well
Alagille syndrome NRH
de Sousa4) 1991 1 female 24 multiple liver tumors 1 year 2,970g NRH well
Budd-Chiari synd.
Elariny5) 1994 1 female 44 cirrhosis 3 years 1,850g NRH well
Nadir6) 1994 2 male 1 60 cirrhosis 2 4 years N /A NRH 2 all well
female 1 (55-64) (4-4 years)
Bernard7) 1995 1 male 34 cirrhosis 14 years 1,070g ISC well
Loinaz8) 1998 4 male 4 35 NRH 1 0.5 years 1,100g NRH 3 died 2 (1, 3 months)
(25-41) cirrhosis 1 (2 months-1 year) (110-2,400g) partial nodular transformation recurrence 1 (7 years)
nodular liver 1
chronic liver disease 1
Radomski9) 2000 4 male 3 46 cirrhosis 4 7.7 years N / A NRH 4 all well
 female 1 (39-55) (4-13 years)
Dumortier10) 2001 8 male 8 45 IPH 8 4.5 years 1,045g ISC 5 all well
(20 - 63) (3-10 years) (630-1,520g) NRH 3
Krasinskas11) 2005 16 male 11 47 cirrhosis 13 4.3 years 1,100g NRH 15 died 1 (5 months)
female 5 (31-64) azathioprine-associated (1-11 years) (600-1,550g) ISC 9 recurrence 2 (3.5, 7 months)
                 liver injury 2
NRH 1
our case 1 female 65 IPH 5 years 620g IPH died　(5 months)
total 40 male 30 45.5 (mean) 4.6 years (mean) 1,150g (mean)
female 10
N / A no available
HCC, hepatocellular carcinoma; IPH, idiopathic portal hypertension; ISC, incomplete septal cirrhosis; NRH, nodular regenerative hyperplasia; LT, liver transplantation





















Transjugular intrahepatic porto-systemic shunts 6(15)
endoscopic variceal ligation 4(10)
mesocaval shunt 3(8)
splenectomy 3(8)
tumorectomy for HCC 1(3)
HCC, hepatocellular carcinoma
Fig. 1A
Fig. 1B
Fig. 1C
